Dual Role of Colchicine in Glioblastoma: miR-22-3p-Dependent Regulation of Wound Healing and Proliferation

Abstract

ABSTRACT Objective: The downregulation of miR-22-3p in glioblastoma (GBM) tissues and cells has been shown to plays a critical role in gliomagenesis and patient prognosis. However, the effects of colchicine on GBM cellular functions via miR-22-3p mediated mechanisms remain unexplored. This study aims to investigate the effects of colchicine on GBM cell behavior through miR-22-3p-mediated mechanisms. Methods: miR-22-3p expression levels were quantified in U87 GBM cells treated with 1, 10, and 100 ng/ml colchicine using qRT-PCR. Cell viability and drug resistance were evaluated using the CCK-8 assay across four groups: temozolomide (TMZ) treated or untreated (i) U87 cells (control), (ii) U87 cells treated with 10 ng/ml colchicine, (iii) U87 cells transfected with a miR-22-3p inhibitor, and (iv) U87 cells transfected with a miR-22-3p inhibitor and 10 ng/ml colchicine. Colony formation was analyzed, migration was assessed using a transwell assay, and wound healing capacity was evaluated via scratch assay, all in U87 cells treated with 10 ng/ml colchicine. Results: Colchicine at 10 ng/ml significantly upregulated miR-22-3p expression. Inhibition of miR-22-3p reversed the colchicine-induced reduction in cell viability and colony formation. Neither colchicine nor miR-22-3p affected the resistance of U87 cells to TMZ. Colchicine reduced U87 cell migration independently of miR-22-3p, while its effect on wound healing was dependent on miR-22-3p expression. Conclusion: This study demonstrates that colchicine modulates miR-22-3p expression and influences key GBM cell functions. These findings provide a preliminary evidence supporting the potential of colchicine as a therapeutic agent in glioblastoma treatment.

Keywords

• Glioblastoma
• colchicine
• miR-22-3p
• transfection
• proliferation
• migration
• wound healing

Glioblastoma Hücrelerinde Kolşisinin Çift Etkisi: miR-22-3p Aracılı Yara İyileşmesi ve Hücre Proliferasyonunun Düzenlenmesi

Öz

ÖZ Amaç: Glioblastoma (GBM) doku ve hücrelerinde miR-22-3p'nin regülasyonu, gliomagenez ve hasta prognozunda kritik bir rol oynamaktadır. Ancak kolçisinin, GBM hücresel fonksiyonları üzerindeki miR-22-3p aracılı mekanizmalar yoluyla olan etkileri henüz araştırılmamıştır. Bu çalışmanın amacı, kolçisinin GBM hücre davranışları üzerindeki etkilerini miR-22-3p aracılı mekanizmalar üzerinden incelemektir. Yöntemler: U87 GBM hücrelerinde 1, 10 ve 100 ng/ml kolçisin uygulaması sonrasında miR-22-3p ekspresyon düzeyleri qRT-PCR ile ölçülmüştür. Hücre canlılığı ve ilaç direnci, CCK-8 testi kullanılarak dört grup üzerinden değerlendirilmiştir: temozolomid (TMZ) uygulanan ya da uygulanmayan (i) kontrol grubu U87 hücreleri, (ii) 10 ng/ml kolçisinle muamele edilen U87 hücreleri, (iii) miR-22-3p inhibitörü ile transfekte edilen U87 hücreleri ve (iv) hem miR-22-3p inhibitörü ile transfekte edilen hem de 10 ng/ml kolçisinle muamele edilen U87 hücreleri. Koloni oluşumu, koloni oluşum testi ile; migrasyon, transwell testi ile; yara iyileşmesi kapasitesi ise çizik (scratch) testi ile, 10 ng/ml kolçisin uygulanan U87 hücrelerinde analiz edilmiştir. Bulgular: 10 ng/ml kolçisin, U87 hücrelerinde miR-22-3p ekspresyonunu anlamlı düzeyde artırmıştır. miR-22-3p inhibisyonu, kolçisinin hücre canlılığı ve koloni oluşumu üzerindeki baskılayıcı etkisini tersine çevirmiştir. Kolçisin veya miR-22-3p, U87 hücrelerinin TMZ’ye olan ilaca direncini etkilememiştir. Kolçisin, hücre migrasyonunu miR-22-3p’den bağımsız olarak azaltırken, yara iyileşmesi üzerindeki etkisi miR-22-3p ekspresyonuna bağımlı olarak gözlenmiştir. Sonuç: Bu çalışma, kolçisinin miR-22-3p ekspresyonunu düzenlediğini ve glioblastoma hücrelerinin temel fonksiyonlarını etkilediğini göstermektedir. Bulgular, kolçisinin glioblastoma tedavisinde potansiyel bir terapötik ajan olarak değerlendirilmesine yönelik ön kanıtlar sunmaktadır.

Anahtar Kelimeler

• Glioblastoma
• kolşisin
• miR-22-3p
• transfeksiyon
• proliferasyon
• migrasyon
• yara iyileşmesi

References

1. 1. Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med 2008; 359(5):492-507.
2. 2. Marenco-Hillembrand L, Wijesekera O, Suarez-Meade P, Mampre D, Jackson C, Peterson J, Trifiletti D, Hammack J, Ortiz K, Lesser E, Spiegel M, Prevatt C, Hawayek M, Quinones-Hinojosa A, Chaichana KL. Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis. J Neurooncol 2020; 147(2):297-307.
3. 3. Jain KK. A Critical Overview of Targeted Therapies for Glioblastoma. Front Oncol 2018; 8:419.
4. 4. Tan AC, Ashley DM, Lopez GY, Malinzak M, Friedman HS, Khasraw M. Management of glioblastoma: State of the art and future directions. CA Cancer J Clin 2020; 70(4):299-312.
5. 5. Weng H, Li J, Zhu H, Carver Wong KF, Zhu Z, Xu J. An update on the recent advances and discovery of novel tubulin colchicine binding inhibitors. Future Med Chem 2023; 15(1):73-95.
6. 6. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010; 9(10):790-803.
7. 7. Rubicondo M, Ciardelli G, Mattu C, Tuszynski JA. Recent advancements in colchicine derivatives: Exploring synthesis, activities, and nanoformulations for enhanced therapeutic efficacy. Drug Discov Today 2025; 30(3):104312.
8. 8. Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res 2012; 29(11):2943-71.

9. 9. Perez-Perez MJ, Priego EM, Bueno O, Martins MS, Canela MD, Liekens S. Blocking Blood Flow to Solid Tumors by Destabilizing Tubulin: An Approach to Targeting Tumor Growth. J Med Chem 2016; 59(19):8685-711.
10. 10. Greene LM, Meegan MJ, Zisterer DM. Combretastatins: more than just vascular targeting agents? J Pharmacol Exp Ther 2015; 355(2):212-27.
11. 11. Barraclough JY, Joglekar MV, Januszewski AS, Martinez G, Celermajer DS, Keech AC, Hardikar AA, Patel S. A MicroRNA Signature in Acute Coronary Syndrome Patients and Modulation by Colchicine. J Cardiovasc Pharmacol Ther 2020; 25(5):444-55.
12. 12. Choi B, Kim HA, Suh CH, Byun HO, Jung JY, Sohn S. The relevance of miRNA-21 in HSV-induced inflammation in a mouse model. Int J Mol Sci 2015; 16(4):7413-27.
13. 13. Hortu HO, Karaca E, Sozeri B, Gulez N, Makay B, Gunduz C, Atik T, Tekin IM, Unsal SE, Cogulu O. Evaluation of the effects of miRNAs in familial Mediterranean fever. Clin Rheumatol 2019; 38(3):635-43.
14. 14. Tumerdem BS, Akbaba TH, Batu ED, Akkaya-Ulum YZ, Mutlu P, Ozen S, Balci-Peynircioglu B. Drug metabolism and inflammation related distinct miRNA signature of colchicine resistant familial Mediterranean fever patients. Int Immunopharmacol 2023; 124(Pt B):111011.
15. 15. Liu P, Chen Y, Wang B, Wang Z, Li C, Wang Y. Expression of microRNAs in the plasma of patients with acute gouty arthritis and the effects of colchicine and etoricoxib on the differential expression of microRNAs. Arch Med Sci 2019; 15(4):1047-55.
16. 16. Chen H, Lu Q, Fei X, Shen L, Jiang D, Dai D. miR-22 inhibits the proliferation, motility, and invasion of human glioblastoma cells by directly targeting SIRT1. Tumour Biol 2016; 37(5):6761-8.
17. 17. Hu T, Wang F, Han G. LncRNA PSMB8-AS1 acts as ceRNA of miR-22-3p to regulate DDIT4 expression in glioblastoma. Neurosci Lett 2020; 728:134896.
18. 18. Ma C, Wang H, Zong G, He J, Wang Y, Yang F, Yang Z, Bian E, Zhao B. EGR1 modulated LncRNA HNF1A-AS1 drives glioblastoma progression via miR-22-3p/ENO1 axis. Cell Death Discov 2021; 7(1):350.
19. 19. Tu J, Fang Y, Han D, Tan X, Xu Z, Jiang H, Wang X, Hong W, Wei W. MicroRNA-22 represses glioma development via activation of macrophage-mediated innate and adaptive immune responses. Oncogene 2022; 41(17):2444-57.
20. 20. Rastegar-Moghaddam SH, Ebrahimzadeh-Bideskan A, Shahba S, Malvandi AM, Mohammadipour A. MicroRNA-22: a Novel and Potent Biological Therapeutics in Neurological Disorders. Mol Neurobiol 2022; 59(5):2694-701.
21. 21. Zhang Y, Tu L, Zhou X, Li B. MicroRNA-22 regulates the proliferation, drug sensitivity and metastasis of human glioma cells by targeting SNAIL1. J BUON 2021; 26(3):1185.
22. 22. Onay O, Kose S, Suslu N, Korkusuz P, Nemutlu E, Aydin C, Hosal S. Human laryngeal squamous cell carcinoma cell line release of endogenous anandamide and 2-arachidonoylglycerol, and their antiproliferative effect via exogenous supplementation: an in vitro study. Cell Tissue Bank 2022; 23(1):93-100.
23. 23. Kose S, Aerts-Kaya F, Kopru CZ, Nemutlu E, Kuskonmaz B, Karaosmanoglu B, Taskiran EZ, Altun B, Uckan Cetinkaya D, Korkusuz P. Human bone marrow mesenchymal stem cells secrete endocannabinoids that stimulate in vitro hematopoietic stem cell migration effectively comparable to beta-adrenergic stimulation. Exp Hematol 2018; 57:30-41 e1.
24. 24. Zhang Y, Tu L, Zhou X, Li B. MicroRNA-22 regulates the proliferation, drug sensitivity and metastasis of human glioma cells by targeting SNAIL1. J BUON 2020; 25(1):491-6.
25. 25. Bisht P, Prasad SR, Choudhary K, Pandey R, Aishwarya D, Aravind V, Ramalingam P, Velayutham R, Kumar N. Naringin and temozolomide combination suppressed the growth of glioblastoma cells by promoting cell apoptosis: network pharmacology, in-vitro assays and metabolomics based study. Front Pharmacol 2024; 15:1431085.
26. 26. Kose S, Onen S, Gizer M, Boduroglu E, Gonullu U, Korkusuz P. Cannabinoid receptor ligands modulate fibrosis and inflammation in idiopathic pulmonary fibrosis: a preliminary study. Turk J Biol 2024; 48(6):379-89.
27. 27. Liu N, Hu G, Wang H, Li Z, Guo Z. PLK1 inhibitor facilitates the suppressing effect of temozolomide on human brain glioma stem cells. J Cell Mol Med 2018; 22(11):5300-10.
28. 28. Kose S, Varan C, Onen S, Nemutlu E, Bilensoy E, Korkusuz P. 2-AG-loaded and bone marrow-targeted PCL nanoparticles as nanoplatforms for hematopoietic cell line mobilization. Stem Cell Res Ther 2024; 15(1):341.
29. 29. Kus G, Oztopcu-Vatan P, Uyar R, Kabadere S. Cytotoxic and apoptotic functions of licofelone on rat glioma cells. Acta Biol Hung 2013; 64(4):438-52.
30. 30. Andrade P, Fraga Dias A, Figueiro F, Torres FC, Kawano DF, Oliveira Battastini AM, Carvalho I, Tomich de Paula da Silva CH, Campos JM. 1,2,3-Triazole tethered 2-mercaptobenzimidazole derivatives: design, synthesis and molecular assessment toward C6 glioma cell line. Future Med Chem 2020; 12(8):689-708.
31. 31. Wang J, Wan Z, Liu W, Li L, Ren L, Wang X, Sun P, Ren L, Zhao H, Tu Q, Zhang Z, Song N, Zhang L. Atomic force microscope study of tumor cell membranes following treatment with anti-cancer drugs. Biosens Bioelectron 2009; 25(4):721-7.
32. 32. Fang KM, Liu JJ, Li CC, Cheng CC, Hsieh YT, Chai KM, Lien YA, Tzeng SF. Colchicine derivative as a potential anti-glioma compound. J Neurooncol 2015; 124(3):403-12.
33. 33. Bhattacharya S, Das A, Datta S, Ganguli A, Chakrabarti G. Colchicine induces autophagy and senescence in lung cancer cells at clinically admissible concentration: potential use of colchicine in combination with autophagy inhibitor in cancer therapy. Tumour Biol 2016; 37(8):10653-64.
34. 34. Chen M, Wang S, Qi Z, Meng X, Hu M, Liu X, Song Y, Deng Y. Deuterated colchicine liposomes based on oligomeric hyaluronic acid modification enhance anti-tumor effect and reduce systemic toxicity. Int J Pharm 2023; 632:122578.
35. 35. Cho JH, Joo YH, Shin EY, Park EJ, Kim MS. Anticancer Effects of Colchicine on Hypopharyngeal Cancer. Anticancer Res 2017; 37(11):6269-80.
36. 36. Oh J, An HJ, Yeo HJ, Choi S, Oh J, Kim S, Kim JM, Choi J, Lee S. Colchicine as a novel drug for the treatment of osteosarcoma through drug repositioning based on an FDA drug library. Front Oncol 2022; 12:893951.
37. 37. Patron LA, Yeoman H, Wilson S, Tang N, Berens ME, Gokhale V, Suzuki TC. Novel Brain-Penetrant, Small-Molecule Tubulin Destabilizers for the Treatment of Glioblastoma. Biomedicines 2024; 12(2).
38. 38. Lai Q, Wang Z, Wu C, Zhang R, Li L, Tao Y, Mo D, Zhang J, Gou L, Wang Y. Design, synthesis, and antitumor evaluation of quinazoline-4-tetrahydroquinoline chemotypes as novel tubulin polymerization inhibitors targeting the colchicine site. Eur J Med Chem 2025; 283:117139.
39. 39. Shawky AM, Almalki FA, Abdalla AN, Youssif BGM, Abdel-Fattah MM, Hersi F, El-Sherief HAM, Ibrahim NA, Gouda AM. Discovery and optimization of 2,3-diaryl-1,3-thiazolidin-4-one-based derivatives as potent and selective cytotoxic agents with anti-inflammatory activity. Eur J Med Chem 2023; 259:115712.
40. 40. Xu C, Wu C, Li L, Zhao H, Liu J, Peng X, Wang Y, Chen J. Discovery of novel thiophene[3,2-d]pyrimidine-based tubulin inhibitors with enhanced antitumor efficacy for combined use with anti-pd-l1 immunotherapy in melanoma. Eur J Med Chem 2024; 277:116791.
41. 41. Adeleye KL, Li AR, Xie Y, Pochampally S, Hamilton D, Garcia-Godoy F, Miller DD, Li W. Novel Antimitotic Agent SP-1-39 Inhibits Head and Neck Squamous Cell Carcinoma. J Dent Res 2024; 103(9):926-36.
42. 42. Han M, Wang S, Fritah S, Wang X, Zhou W, Yang N, Ni S, Huang B, Chen A, Li G, Miletic H, Thorsen F, Bjerkvig R, Li X, Wang J. Interfering with long non-coding RNA MIR22HG processing inhibits glioblastoma progression through suppression of Wnt/beta-catenin signalling. Brain 2020; 143(2):512-30.
43. 43. Zhang Z, Xu J, Chen Z, Wang H, Xue H, Yang C, Guo Q, Qi Y, Guo X, Qian M, Wang S, Qiu W, Gao X, Zhao R, Guo X, Li G. Transfer of MicroRNA via Macrophage-Derived Extracellular Vesicles Promotes Proneural-to-Mesenchymal Transition in Glioma Stem Cells. Cancer Immunol Res 2020; 8(7):966-81.
44. 44. Zhang T, Chen W, Jiang X, Liu L, Wei K, Du H, Wang H, Li J. Anticancer effects and underlying mechanism of Colchicine on human gastric cancer cell lines in vitro and in vivo. Biosci Rep 2019; 39(1).